» Articles » PMID: 36718082

Follistatin Forms a Stable Complex With Inhibin A That Does Not Interfere With Activin A Antagonism

Abstract

Inhibins are transforming growth factor-β family heterodimers that suppress follicle-stimulating hormone (FSH) secretion by antagonizing activin class ligands. Inhibins share a common β chain with activin ligands. Follistatin is another activin antagonist, known to bind the common β chain of both activins and inhibins. In this study, we characterized the antagonist-antagonist complex of inhibin A and follistatin to determine if their interaction impacted activin A antagonism. We isolated the inhibin A:follistatin 288 complex, showing that it forms in a 1:1 stoichiometric ratio, different from previously reported homodimeric ligand:follistatin complexes, which bind in a 1:2 ratio. Small angle X-ray scattering coupled with modeling provided a low-resolution structure of inhibin A in complex with follistatin 288. Inhibin binds follistatin via the shared activin β chain, leaving the α chain free and flexible. The inhibin A:follistatin 288 complex was also shown to bind heparin with lower affinity than follistatin 288 alone or in complex with activin A. Characterizing the inhibin A:follistatin 288 complex in an activin-responsive luciferase assay and by surface plasmon resonance indicated that the inhibitor complex readily dissociated upon binding type II receptor activin receptor type IIb, allowing both antagonists to inhibit activin signaling. Additionally, injection of the complex in ovariectomized female mice did not alter inhibin A suppression of FSH. Taken together, this study shows that while follistatin binds to inhibin A with a substochiometric ratio relative to the activin homodimer, the complex can dissociate readily, allowing both proteins to effectively antagonize activin signaling.

Citing Articles

Interplay Between Diet, Branched-Chain Amino Acids, and Myokines in Children: Vegetarian Versus Traditional Eating Habits.

Ambroszkiewicz J, Chelchowska M, Mazur J, Rowicka G, Klemarczyk W, Strucinska M Nutrients. 2025; 17(5).

PMID: 40077702 PMC: 11901508. DOI: 10.3390/nu17050834.


Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis.

Swain S, Narayan R, Mishra P Front Cell Dev Biol. 2024; 12:1461278.

PMID: 39239563 PMC: 11374643. DOI: 10.3389/fcell.2024.1461278.

References
1.
Dyer K, Hammel M, Rambo R, Tsutakawa S, Rodic I, Classen S . High-throughput SAXS for the characterization of biomolecules in solution: a practical approach. Methods Mol Biol. 2013; 1091:245-58. PMC: 4057279. DOI: 10.1007/978-1-62703-691-7_18. View

2.
Hart K, Stocker W, Nagykery N, Walton K, Harrison C, Donahoe P . Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-β family. Proc Natl Acad Sci U S A. 2021; 118(26). PMC: 8256043. DOI: 10.1073/pnas.2104809118. View

3.
Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N . Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem. 1993; 268(21):15579-87. View

4.
Thompson T, Woodruff T, Jardetzky T . Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. EMBO J. 2003; 22(7):1555-66. PMC: 152900. DOI: 10.1093/emboj/cdg156. View

5.
Bernard D, Chapman S, Woodruff T . Mechanisms of inhibin signal transduction. Recent Prog Horm Res. 2001; 56:417-50. DOI: 10.1210/rp.56.1.417. View